复肝宁对免疫性肝纤维化大鼠HYP SOD MDA的影响

目的:通过大鼠肝纤维化动物模型,研究中药复方复肝宁治疗肝纤维化的效果及部分作用机制。方法:采用猪血清诱导免疫性肝纤维化动物模型。70只大鼠随机分6组:正常组,模型组,秋水仙碱治疗组,复肝宁低、中、高剂量治疗组。造模6周后,各组大鼠给予相应的药物或生理盐水灌胃。实验第10周末,处死动物,并采集肝组织标本。测定肝组织羟脯氨酸(HYP)含量、丙二醛(MDA)含量、超氧化物歧化酶(SOD)活性,通过光镜观察肝病理组织学改变。结果:与正常组比较,模型组大鼠肝组织HYP含量明显升高(P<0.01)。复肝宁高、中剂量组、秋水仙碱组与模型组比较,HYP(P<0.01);复肝宁低剂量组与模型组比较,HYP(P<0.05)。复肝宁能使肝纤维化大鼠组织SOD活性升高,MDA含量下降。病理学观察显示:与正常组比较,模型组大鼠肝脏出现典型的肝纤维化表现;各治疗组肝纤维化程度较模型组显著降低,特别是复肝宁高剂量治疗组(P<0.01)。结论:复肝宁对猪血清诱导的肝纤维化大鼠有确切治疗作用,其机制是清除氧自由基,抑制脂质过氧化,抑制胶原合成,促进胶原降解。

Effects of FuGanNing on Serum HYP SOD and MDA in Rats with Immune Hepatic Fibrosis

Objective:To study the therapeutic effect and mechanism of FuGanNing on rat with immune hepatic fibrosis induced by porcine serum injection.Methods: The immune hepatic fibrosis model was induced intraperitoneal injection of porcine serum. Seventy Wistar rats were randomly divided into six groups: normal group, model group, colchincines group, low, middle and high dose FuGanNing groups. After 6 weeks, all rats were given medicine via gastrogavage respectively. At the end of 10th weeks, all rats were sacrificed. The serum levels of hydroxyproline (HYP) content, malondial dehyde (MDA) content, superoxide disumutase (SOD) activity of liver tissue were measured respectively. The histological changes of liver tissue were observed with optic microscope.Results: Compared with normal group, the content HYP of the model group were significantly increased (P<0.01). The levels of HYP of high and middle dose group were lower than that of model group, namely, HYP (P<0.01). The levels of HYP of low dose group were lower than that of model group (P<0.05). The levels of HYP of colchincines group were lower than that of model group, namely HYP (P<0.01). Compared with model group, the MDA content of FuGanNing groups were reduced and the SOD activity of FuGanNing groups were increased. Pathological observation: Compared with the normal group, the model group had shown typical hepatic fibrosis. The degree of hepatic fibrosis of all treatment groups was lower than that of the model group, especially that of high dose group (P<0.01).Conclusion: FuGanNing is very efficient in treating hepatic fibrosis. Eliminating Oxygen Radicals, suppressing lipid peroxideand and decreasing the levels of ECM may be its therapeutic mechanism.